drugset / Trial / NCT05198336

Immunogenicity of an Inactivated COVID-19 Vaccine

NCT05198336

Phase 4 Completed 395 enrolled Sinovac Research and Development Co., Ltd.
Non-randomizedParallel-groupOpen-labelPrevention

Summary

This study is an open phase 4 clinical trial of an inactivated COVID-19 vaccine (CoronaVac) manufactured by Sinovac Research and Development Co., Ltd. The purpose of this study is to evaluate the immunogenicity of the CoronaVac in healthy children aged 3-11 years old.

Timeline

Start
2022-01-08
Primary completion
2022-01-24
Completion
2022-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject CoronaVac Vaccine 600 unknown

Indications